Open access · CC-BY
via OpenAlex
Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?
Yuval Gavriel, Irena Voinsky, Hana Klin, Alessio Squassina, David Gurwitz
Drug Development Research · 2025 · ▲ 3 citations
Abstract
Taurine is an atypical amino acid that cannot form peptide bonds and thus does not take place in building proteins. Yet, taurine takes part in regulating many cell functions, including cell osmolarity and volume, mitochondrial function, membrane ion channels and neuronal activity, and cell survival. Taurine is synthesized by the liver, and available from consumption of meat and fish, but not plants. It has millimolar concentrations in the brain, skeletal muscle, blood, heart, retina, and other tissues. Taurine is transported from the liver (following synthesis) or the intestine (following consumption) to blood by the taurine transporter, encoded in humans by SLC6A6. A recent study reported that blood taurine declines dramatically in aged individuals. Several studies indicated that dietary taurine slows cognitive decline in Alzheimer's disease (AD) model mice. We therefore measured SLC6A6 mRNA expression in human lymphoblastoid cell lines (LCLs) from AD patients and age-matched controls and observed 2.8-fold lower expression in AD LCLs (p = 0.0005). Additionally, glutathione peroxidase 1 (GPX1), a key free-radical scavenging selenoenzyme, had reduced mRNA expression in LCLs from AD patients compared with controls. Our observations suggest that reduced taurine transporter expression may contribute to AD pathogenesis and that dietary taurine might be beneficial for slowing disease progression in early-stage AD. Clinical trials with dietary taurine supplementation of individuals with mild cognitive impairment (MCI) or early-stage AD are required to assess its tentative therapeutic potential.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ddr.70124
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
Gavriel, Y., Voinsky, I., Klin, H., Squassina, A., & Gurwitz, D. (2025). Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?. <em>Drug Development Research</em>. https://doi.org/10.1002/ddr.70124
Vancouver
Gavriel Y, Voinsky I, Klin H, Squassina A, Gurwitz D. Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?. Drug Development Research. 2025. doi:10.1002/ddr.70124.
BibTeX
@article{yuval2025Reduce,
title = {Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age‐Matched Controls: Therapeutic Implications?},
author = {Yuval Gavriel and Irena Voinsky and Hana Klin and Alessio Squassina and David Gurwitz},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70124},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Drug development research 2025
Open access · OA
Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age-Matched Controls: Therapeutic Implications?
Metabolites 2022
Open access · CC-BY
Involvement of TauT/SLC6A6 in Taurine Transport at the Blood–Testis Barrier
Scientific Reports 2018
Open access · CC-BY
SIRT1, miR-132 and miR-212 link human longevity to Alzheimer’s Disease
Nutrients 2024
Open access · CC-BY
Reduced Taurine Serum Levels in Inflammatory Bowel Disease
Journal of Translational Medicine 2015
Open access · CC-BY
Taurine: the appeal of a safe amino acid for skeletal muscle disorders
The Journal of Immunology 2007
Open access · OA